Xellia Pharmaceuticals ApS

About Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

  • DK
  • 2015
    On CPHI since
  • 1000 - 4999
Company types
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Frankfurt, Germany
1-3 November 2022

Products from Xellia Pharmaceuticals ApS (5)

  • Amphotericin B

    Product Amphotericin B

    Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.

    Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients.
  • Bacitracin

    Product Bacitracin

    Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

    Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the tr...
  • Bacitracin zinc

    Product Bacitracin zinc

    Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

    Indication: Used in the treatment...
  • Colistimethate sodium (CMS)

    Product Colistimethate sodium (CMS)

    Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

  • Colistin sulfate

    Product Colistin sulfate

    Colistin sulfate is a mixture of sulfates of polypeptide antibiotics active against Gram-negative bacteria including Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli and Klebsiella pneumoniae.

    Indication: Used in the treatment of acute infections due...

Xellia Pharmaceuticals ApS Resources (4)

  • News Xellia Pharmaceuticals Cleveland, Ohio manufacturing facility commercially operational for production of key anti-infective drug products for US hospitals and patients

    Copenhagen, Denmark, and Buffalo Grove, Illinois, US, 17 August 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
  • Brochure Xellia Pharmaceuticals Corporate Report 2020

    Committed to patients in a year impacted by COVID-19During 2020, our main focus was on maintaining full production and reliable supply of Xellia’s critical care products, while also ensuring the safety of our employees.

    Read more in Xellia's Corporate Report 2020
  • Video Corporate film

    Xellia Pharmaceuticals operates internationally, with sales offices and production sites found across the globe. Xellia Pharmaceuticals is the leading supplier of important anti-infectives vancomycin, colistimethate sodium and daptomycin. We are vertically integrated from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs), with 150+ research and development scientists, and robust production sites.
  • Video Molecule to Market: Podcast with Carl-Åke Carlsen, CEO & President, Xellia Pharmaceuticals

    We are pleased to share the podcast: Molecule to Market – featuring our CEO, Carl-Åke Carlsson. The host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke, covering Xellia’s journey from an API supplier to a global specialty pharmaceutical company; producing anti-infective treatments. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years; offering advice and insight from his experiences. Molecule to Market is sponsored and funded by Ramarketing, an international content, design and digital agency. Click the link here to access the podcast: https://apple.co/32a0RW0 or at https://spoti.fi/3jXjgLS